A detailed history of Jump Financial, LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Jump Financial, LLC holds 43,099 shares of BEAM stock, worth $1.13 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
43,099
Holding current value
$1.13 Million
% of portfolio
0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$22.57 - $33.14 $972,744 - $1.43 Million
43,099 New
43,099 $1.06 Million
Q3 2023

Oct 21, 2024

BUY
$23.01 - $32.46 $117,466 - $165,708
5,105 Added 18.75%
32,330 $777,000
Q3 2023

Nov 07, 2023

BUY
$23.01 - $32.46 $117,466 - $165,708
5,105 Added 18.75%
32,330 $777,000
Q2 2023

Oct 21, 2024

BUY
$29.32 - $35.99 $798,237 - $979,827
27,225 New
27,225 $869,000
Q2 2023

Aug 07, 2023

BUY
$29.32 - $35.99 $798,237 - $979,827
27,225 New
27,225 $869,000
Q4 2022

Feb 13, 2023

BUY
$36.73 - $51.6 $1.38 Million - $1.93 Million
37,463 New
37,463 $1.47 Million
Q2 2022

Aug 09, 2022

BUY
$29.86 - $62.36 $252,854 - $528,064
8,468 Added 15.93%
61,614 $2.39 Million
Q1 2022

May 12, 2022

BUY
$53.73 - $82.16 $2.86 Million - $4.37 Million
53,146 New
53,146 $3.05 Million
Q4 2021

Feb 10, 2022

SELL
$68.02 - $99.06 $1.33 Million - $1.94 Million
-19,570 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$84.37 - $133.6 $1.65 Million - $2.61 Million
19,570 New
19,570 $1.7 Million
Q2 2021

Aug 13, 2021

SELL
$64.12 - $128.71 $1.75 Million - $3.52 Million
-27,338 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$71.28 - $120.75 $1.95 Million - $3.3 Million
27,338 New
27,338 $2.19 Million

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.85B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.